IP Library › Granted Patent US 12,653,811
Granted Patent B2
US 12,653,811 · App. 17/923,641 · Granted Jun 16, 2026

Dosage regimen of amlodipine

Inventors: Andrew John McGlashan Richards (Babraham, GB); Paul Goldsmith (Babraham, GB); David Collier (Babraham, GB); David Cox (Babraham, GB); Bruce Campbell (Babraham, GB)
Assignee: CLOSED LOOP MEDICINE LTD
A61K31/4422G16H20/10G16H50/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,653,811
App. No.
17/923,641
Granted
Jun 16, 2026
Kind
B2
Abstract

There is a dosage regimen for amlodipine for use in the treatment of hypertension.

Claims (28)

1 . A method for treating hypertension in a patient with a dosage regimen, wherein the dosage regimen comprises:

i. for a period of from about 7 days to about 14 days:

a) administering an initial daily dose of 1 to 10 mg amlodipine to the patient;

b) recording patient's blood pressure readings on at least 3 separate days, using a blood pressure device;

c) recording any side-effects experienced by the patient on at least 3 separate days;

ii. increasing or decreasing the daily dose of amlodipine by between 1 mg and 2.5 mg, or maintaining the daily dose of amlodipine, based on the blood pressure readings and the patient reported side-effects; and

iii. repeating steps (i) and (ii) with either the increased, decreased or maintained daily dose replacing the initial daily dose in step (a) for a number of times until a specified patient treatment period has elapsed or until a target blood pressure is reached.

2 . The method according to claim 1 , wherein step b) includes a determination of a moving average of the blood pressure readings and the increasing, decreasing or maintaining the daily dose in step (ii) is based on the moving average of the blood pressure.

3 . The method according to claim 2 , wherein the moving average is a 3-day moving average, wherein the days are consecutive.

4 . The method according to claim 1 , wherein the period in step (i) is either pre-determined or is determined by the time taken to reach less than 10% variability in the moving average blood pressure.

5 . The method according to claim 1 , wherein the blood pressure readings are recorded at least every other day.

6 . The method according to claim 1 , wherein blood pressure readings are recorded at the same time each day.

7 . The method according to claim 1 , wherein the patient's initial daily dose is determined based on their medical history and/or history of prior side-effects when taking amlodipine.

8 . The method according to claim 1 , wherein the patient's initial daily dose is determined by a physician or delegated health care professional.

9 . The method according to claim 1 , wherein the patient's initial daily dose is 1 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg or 6 mg.

10 . The method according to claim 1 , wherein the patients are selected for treatment if the patients have had a diagnosis of hypertension according to NICE/BIHS CG127 criteria, and wherein the patients have already had conducted 24h ambulatory blood pressure monitoring (ABPM) recording or home blood pressure monitoring.

11 . The method according to claim 1 , wherein the increasing or decreasing is in an increment of 1 mg, 2 mg or 2.5 mg.

12 . The method according to claim 1 , wherein the increasing or decreasing in step (ii) includes a comparison of the blood pressure with a control blood pressure and/or a dose/response curve for amlodipine personalised for the patient.

13 . The method according to claim 1 , wherein step (ii) is carried out by a physician or delegated health care professional or wherein step (ii) is carried out by software executed on an electronic device.

14 . The method according to claim 1 , wherein the recording of blood pressure is onto an electronic device.

15 . The method according to claim 14 , wherein data are transferred from the blood pressure device to the electronic device electronically and automatically.

16 . The method according to claim 1 , wherein the modification of the dose in step (ii) is based on patient tolerability of the side-effects.

17 . The method according to claim 1 , wherein the side-effects recorded by the patient are selected from the group consisting of one or more of swollen ankles, feet, and legs.

18 . The method according to claim 1 , wherein the side-effects recorded by the patient include hypotension.

19 . The method according to claim 1 , wherein the side-effects recorded by the patient include hypotension and one or more selected from the group consisting of swollen ankles, feet, and legs.

20 . The method according to claim 1 , wherein the recording of the side-effects is carried out daily.

21 . The method according to claim 1 , wherein the amlodipine is administered in solid form and via the oral route.

22 . The method of claim 1 comprising recording the patient's blood pressure on at least 3 separate days and calculating a moving average of the blood pressure and producing an amlodipine dosage regimen based on the moving average of the blood pressure readings and the patient reported side effects.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2026
From: CLOSED LOOP MEDICINE LIMITED
To: MORCHELLA MEDICAL LIMITED
Reel/Frame 075917/0640 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 12, 2023
From: RICHARDS, ANDREW JOHN MC GLASHAN; GOLDSMITH, PAUL; COLLIER, DAVID; CAMPBELL, BRUCE
To: CLOSED LOOP MEDICINE LTD
Reel/Frame 065200/0625 →
Priority Claims (1)
GB 2006819 · May 7, 2020 · national
Continuity (1)
Related Publication 20230181551A1 · Jun 15, 2023
References Cited (26)
US 6057344A · Young · 2000 [cited by examiner]
US 6162802A · Papa · 2000 [cited by examiner]
US 11096595B2 · Albadawi · 2021 [cited by examiner]
US 20030022922A1 · Lemmens · 2003 [cited by examiner]
US 20040254176A1 · Grigorieff et al. · 2004 [cited by applicant]
US 20080027291A1 · Williams-Hartman · 2008 [cited by applicant]
JP 2006306754A · 2006 [cited by applicant]
Webb (https://www.pmsinstruments .co.uk/blog/pms-algorithm-for-blood-pressure-measurement/, Jul. 2014). (Year: 2014). [cited by examiner]
Ombani (Frontiers in Cardiovascular Medicine, 2019, 6, 40, p. 1-7). (Year: 2019). [cited by examiner]
International Preliminary Report on Patentability dated Nov. 8, 2022 from corresponding International (PCT) Patent Application No. PCT/GB2021/051112, 8 pages. [cited by applicant]
Frick et al.; “Amlodipine: A Double-Blind Evaluation of the Dose-Response Relationship in Mold to Moderate Hypertension”, Journal of Cardiovascular Pharmacology, vol. 12 (Suppl. 7), 1988, pp. S76-S78. [cited by applicant]
Mukherjee et al.; “Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model”, Journal of Pharmacokinetics and P… [cited by applicant]
Murdoch et al.; “Amlodipine A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Cardiovascular Disease”, Drugs, Adis International Ltd., vol. 41 (3) 1991, pp. 478-505. [cited by applicant]
Osterloh, Ian; “The safety of amlodipine”, American Heart Journal, vol. 118, No. 5, Part 2, Nov. 1989, pp. 1114-1120. [cited by applicant]
International Search Report dated Aug. 25, 2021 from corresponding International (PCT) Patent Application No. PCT/GB2021/051112, 4 pages. [cited by applicant]
Written Opinion dated Aug. 25, 2021 from corresponding International (PCT) Patent Application No. PCT/GB2021/051112, 7 pages. [cited by applicant]
Amlodipine Patient Insert Leaflet NDA 19-787/S-042, 14 pages. [cited by applicant]
Donnelly et al., Pharmacodynamic modelling of the antihypertensive response to amlodipine, Clinical Pharmacology & Therapeutics, Oct. 1993, pp. 303-310. [cited by applicant]
FDA Amlodipine Approval Clinical Pharmacology and Biopharmaceutical Review (2002), NDA 19-787/S30, 36 pages. [cited by applicant]
Heo et al.; “Quantitative model for the blood pressure lowering interaction of valsartan and amlodipine”; Br J Clin Pharmacol (2016), 82, 1557-1567. [cited by applicant]
Williams et al.; “Amlodipine Pharmacokinetics in Healthy Volunteers”; J Clin Pharm (1988), 28, 990-994. [cited by applicant]
Japanese Notice of Reasons for Refusal dated Mar. 18, 2025 from corresponding Japanese Patent Application No. 2022-566669, 12 pages. [cited by applicant]
Kai, Hisashi; “Timing of increasing or decreasing antihypertrensive medication”; Medicina, 2016, vol. 53, No. 11, pp. 1784-1788. [cited by applicant]
Makino et al.; “Efficacy of carvedilol in patients with chronic heart failure”, Medical Treatment and New Drugs, vol. 40, No. 7, Jul. 2003, 10 pages. [cited by applicant]
Sugimoto, Koichi; “How to use antihypertensive drugs”, Medical Online, Resident Note, vol. 9, No. 6, Sep. 2007, pp. 799-808. [cited by applicant]
Ura et al.; “A review of current hypertension treatments”, Circulation Control, vol. 25, No. 2, 2004, pp. 108-113. [cited by applicant]